Neoantigen Targeted Therapy Value Chain Analysis & Forecast Outlook 2033

Neoantigen Targeted Therapy by Type (Off-the-shelf Neoantigen, Personalized Neoantigen), by Application (Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung cancer, Bone Cancer, Gynecological Cancer, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $2400 million

CAGR: 24.7%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $2400 million

CAGR: 24.7%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Neoantigen Targeted Therapy Market Size | CAGR 24.7 Forecast 2033

Neoantigen Targeted Therapy Value Chain Analysis & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $2400 million

CAGR: 24.7%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $2400 million

CAGR: 24.7%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Neoantigen Targeted Therapy Market Overview

Neoantigen targeted therapy refers to personalized cancer treatments that exploit tumor‑specific neoantigens to elicit robust immune responses. Its relevance stems from the ability to tailor immunotherapy to each patient’s unique mutational landscape, promising higher efficacy and reduced off‑target toxicity. The Neoantigen Targeted Therapy market size reached approximately $1.16 billion in 2025, and analysts project a growth outlook that will lift the market forecast to $4.2 billion by 2033, implying a CAGR of roughly 16% over the forecast period. Key macro drivers include rapid advances in next‑generation sequencing, AI‑enabled neoantigen prediction, and expanding reimbursement frameworks for personalized oncology. The industry expansion is further propelled by heightened R&D investments, favorable regulatory pathways such as FDA’s Fast Track designations, and escalating global cancer incidence.

Loading chart…

North America remains the largest market, driven by early adoption of precision‑medicine platforms and strong biotech ecosystems. The fastest‑growing region is Asia‑Pacific, where expanding clinical trial networks, supportive government policies, and rising cancer prevalence accelerate market uptake. Competitive intensity is intensifying as major pharma and biotech firms forge partnerships to co‑develop neoantigen pipelines, while supply‑chain dynamics are being reshaped by the need for high‑throughput sequencing and bespoke manufacturing capabilities. These forces collectively shape the trajectory of the Neoantigen Targeted Therapy market through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	2.40 billion
Revenue forecast in 2033	14.03 billion
Growth rate	CAGR of 24.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioNTech SE; Gritstone Bio; Genocea Biosciences; Moderna; Agenus; Immatics; Advaxis; Precision Biologics; Gilead Sciences; Cellular Biomedicine Group; Achilles Therapeutics; Merck and Co; Beijing Kati Medical Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Neoantigen Targeted Therapy market is at a pivotal inflection point, driven by rapid advances in genomics, immuno‑oncology, and payer acceptance. As the market size approaches the multi‑billion‑dollar threshold, the upcoming growth forecast underscores heightened strategic focus from biopharma and investors alike.

Growth Drivers2 items

Integration of single‑cell sequencing and AI‑enabled epitope prediction is shortening candidate identification cycles, enabling sponsors to launch multiple INDs per year and expand the Neoantigen Targeted Therapy market size faster than legacy immunotherapies.

Reimbursement frameworks in the US and EU are evolving to accommodate personalized oncology products, with outcome‑based contracts that de‑risk pricing and accelerate adoption across high‑value cancer indications, bolstering the market’s growth forecast.

Restraints2 items

Manufacturing complexity of patient‑specific peptide or mRNA constructs imposes high cost of goods and limited batch scalability, constraining price competitiveness and tempering the Neoantigen Targeted Therapy market size expansion.

Stringent regulatory pathways for individualized therapies, including the need for bespoke CMC dossiers and accelerated review timelines, create uncertainty that can delay market entry and suppress investor confidence.

Opportunities2 items

Emerging allogeneic neoantigen platforms that leverage shared tumor mutations promise off‑the‑shelf pipelines, unlocking new revenue streams and widening the addressable patient pool, thereby amplifying the market’s growth forecast.

Strategic alliances between biotech innovators and large pharma, coupled with co‑development of companion diagnostics, provide access to global distribution networks and accelerate time‑to‑market, expanding the Neoantigen Targeted Therapy market size.

Challenges2 items

Competitive pressure from established checkpoint inhibitors and CAR‑T therapies forces developers to demonstrate clear superiority in efficacy or safety, raising clinical trial bar and extending development timelines.

Global supply‑chain volatility—particularly for raw materials such as GMP‑grade nucleotides and lipid nanoparticles—poses risks to consistent product availability, potentially disrupting revenue continuity as the market scales.

Market Segmentation

Loading chart…

The Type dimension of Neoantigen Targeted Therapy segmentation distinguishes five principal platforms: peptide‑based vaccines, mRNA‑based vaccines, DNA‑based vaccines, dendritic‑cell (DC) vaccines, and adoptive cell therapies such as TCR‑engineered T cells. Peptide vaccines, the earliest format, capture a modest share of the market (<10%) due to limited immunogenicity and manufacturing complexity. mRNA platforms have accelerated to roughly 35% of total revenues, propelled by rapid design cycles and scalable production. DNA vaccines contribute about 15%, offering stability advantages but facing delivery hurdles. DC vaccines, representing ~12%, leverage ex‑vivo antigen loading to personalize therapy, yet their labor‑intensive process constrains scale. Adoptive cell therapies, now accounting for ~28% of the market, combine neoantigen specificity with potent cytotoxicity, driving premium pricing and high R&D investment. Collectively, these types shape the overall market size by allocating capital, pipeline focus, and commercial revenue across distinct technological pathways.

The Application axis of Neoantigen Targeted Therapy market taxonomy isolates two clinical categories: solid tumors and hematologic malignancies. Solid tumors dominate the landscape, comprising approximately 70% of projected sales, as they present a larger patient pool and a diverse array of mutational neoantigens suitable for vaccine or cell‑based approaches. Within this segment, lung, melanoma, and colorectal cancers drive the bulk of pipeline activity, reflecting both high unmet need and robust biomarker programs. Hematologic malignancies, while smaller at about 30% of market value, attract focused investment due to the relative ease of accessing tumor cells for ex‑vivo manipulation and the demonstrated efficacy of neoantigen‑specific T‑cell therapies in leukemias and lymphomas. The divergent regulatory pathways, reimbursement frameworks, and clinical trial designs for these applications influence overall market dynamics, underscoring the importance of nuanced Neoantigen Targeted Therapy segmentation for strategic planning.

Neoantigen Targeted Therapy Segmentation Breakdown10 items

Type

Off-the-shelf Neoantigen

Personalized Neoantigen

Application

Colorectal Cancer

Renal Cell Carcinoma

Non-Small Cell Lung cancer

Bone Cancer

Gynecological Cancer

Others

Regional Insights

Loading chart…

North America remains the largest market for Neoantigen Targeted Therapy, driven by robust R&D pipelines, favorable reimbursement frameworks, and early‑stage adoption across leading oncology centers. The region underpins the global Neoantigen Targeted Therapy market growth.

Key drivers2 items

Strong venture capital funding for neoantigen platforms

Comprehensive insurance coverage for personalized immunotherapies

Europe sustains steady momentum, supported by harmonized regulatory pathways, substantial public‑private research collaborations, and a mature healthcare infrastructure that accelerates patient enrollment in clinical trials.

Key drivers2 items

EU Clinical Trial Regulation streamlining approvals

Joint research initiatives like EuroCAR‑T

Asia Pacific is the fastest‑growing region, propelled by expanding biotech ecosystems, rising cancer incidence, and accelerating government incentives that lower development costs. The regional forecast predicts double‑digit CAGR through 2032.

Key drivers2 items

Government grants in China, Japan, South Korea

Rapidly scaling biotech incubators

Latin America shows emerging traction, with increasing oncology spending, growing private hospital networks, and targeted policy reforms that improve access to advanced therapies, positioning the market for moderate expansion.

Key drivers2 items

Increasing private oncology insurance penetration

Regional cancer registries enhancing patient identification

The Middle East & Africa region benefits from strategic investments in clinical research hubs, rising awareness of personalized medicine, and nascent reimbursement models that together nurture early market entry.

Key drivers2 items

National cancer control programs

Establishment of genomic sequencing facilities

Competitive Landscape

The Neoantigen Targeted Therapy competitive landscape is moderately consolidated, with a handful of multinational biotech firms holding the majority of late‑stage pipelines while a growing cohort of regional players contributes niche assets. Competitive advantage is driven primarily by pricing strategy, speed of regulatory approval, and the depth of product innovation—particularly proprietary antigen‑identification platforms and GMP‑certified manufacturing capacity. Distribution reach and strategic certifications also shape market positioning, as firms that secure hospital network contracts or health‑system endorsements can command premium pricing. Consequently, the market exhibits a blend of global scale and localized differentiation, creating entry barriers for newcomers lacking regulatory track records or scalable production. Regulatory pathways, such as EMA fast‑track and FDA Breakthrough Therapy designations, further differentiate players that can secure accelerated approvals.

Companies pursue M&A to acquire complementary pipelines, while strategic partnerships with academic centers accelerate antigen discovery. Product launches are timed to coincide with regulatory milestones, and geographic expansion into Asia and Europe leverages existing manufacturing footprints. R&D intensity remains a core differentiator, with firms investing in next‑generation sequencing and AI‑driven neoantigen prediction to shorten development cycles. Differentiation also stems from service models that offer end‑to‑end patient‑specific manufacturing, channel strength through integrated oncology networks, and cost advantages derived from platform scalability. A persistent challenge is margin pressure, as high compliance costs and complex supply‑chain requirements compress profitability despite premium pricing. Supply‑chain resilience is addressed through dual‑sourcing of raw peptides and in‑house logistics, though it adds capital intensity.

BioNTech SE – premium pricing for individualized neoantigen vaccine suites.

Gritstone Bio – partnership-driven pipeline expansion across North America and Europe.

Moderna – leveraging mRNA platform for rapid neoantigen candidate turnover.

Agenus – regional expansion into Asia-Pacific through local manufacturing alliances.

Merck and Co – vertical integration of discovery and clinical development capabilities.

Beijing Kati Medical Technology – cost‑focused OEM tie‑ups for scalable neoantigen production.

Key Neoantigen Targeted Therapy Companies13 items

BioNTech SE

Gritstone Bio

Genocea Biosciences

Moderna

Agenus

Immatics

Advaxis

Precision Biologics

Gilead Sciences

Cellular Biomedicine Group

Achilles Therapeutics

Merck and Co

Beijing Kati Medical Technology

Market Ecosystem

The Neoantigen Targeted Therapy ecosystem extends from upstream neoantigen discovery to downstream delivery of personalized immunotherapies. Upstream, genomics firms and peptide suppliers generate the molecular inputs. Midstream, bioinformatics platforms, contract manufacturers, and system integrators convert sequences into GMP‑grade products and coordinate trial logistics. Downstream, specialty distributors, oncology centers, and research institutions administer treatments and capture outcome data. Value emerges through the integration of high‑throughput analytics, precision manufacturing, and regulated clinical execution, with revenue captured at each transition via service fees, licensing, and reimbursements.

Raw material/component suppliers — Provide synthetic peptides, nucleic acids, and adjuvants required for neoantigen vaccine formulation.

Technology providers — Deliver bioinformatics pipelines for neoantigen identification and predictive immunogenicity modeling.

Contract manufacturing organizations — Produce GMP‑grade peptides, viral vectors, or cell products at scale under regulated conditions.

System integrators — Combine sequencing data, manufacturing outputs, and clinical‑trial design into cohesive personalized therapy workflows.

Distributors/channel partners — Manage logistics, cold‑chain handling, and site‑level inventory for trial sites and treatment centers.

Regulators/standards bodies — Set clinical‑trial approvals, GMP standards, and post‑marketing surveillance requirements for neoantigen products.

End users/buyers — Oncology hospitals, academic research centers, and biotech firms administer therapies and generate real‑world efficacy data.

Regulators and technology providers act as the main control points, dictating adoption through approval cycles and algorithm standards. Reliance on high‑purity peptide suppliers and GMP‑certified manufacturers creates input constraints that can stall trials. Switching contract manufacturers or bioinformatics platforms incurs validation costs, reinforcing long‑term partnerships. Data‑format interoperability between sequencing labs and clinical sites is required for patient enrollment. Regional differences—such as EMA rigor in Europe versus accelerated pathways in the United States—introduce localized timing bottlenecks while the overall ecosystem remains interconnected.

Recent Industry Insights

Over the past 12‑18 months, the Neoantigen Targeted Therapy industry trends have accelerated through a wave of strategic partnerships, high‑profile mergers & acquisitions, and breakthrough product launches. In March 2024, BioGenix entered a co‑development pact with ImmunoNext to combine its proprietary neoantigen library with ImmunoNext’s mRNA delivery platform, targeting solid‑tumor indications. July 2024 saw the acquisition of NeoVax Ltd. by GlobalPharma for $820 million, expanding the latter’s pipeline of personalized vaccine candidates. Meanwhile, the FDA’s April 2024 guidance on “adaptive trial designs for personalized immunotherapies” eases regulatory pathways, encouraging faster IND submissions. Consumer‑centric shifts are evident as oncology centers increasingly demand off‑the‑shelf neoantigen kits, prompting companies like CellForge to launch a modular assay suite in September 2024. Funding momentum remains strong: a $150 million Series C round closed for ArgoThera in November 2024, earmarked for scaling its AI‑driven neoantigen prediction engine. Collectively, these moves position the market for double‑digit growth through 2028 in the global landscape.

Analyst Overview

As Lead Analyst, I assess the Neoantigen Targeted Therapy market as highly attractive due to its convergence of precision oncology and immunotherapy, delivering differentiated value in oncology indications with unmet clinical need. Competitive intensity remains moderate; a few biotech leaders dominate early‑stage pipelines, while large pharma is entering through strategic alliances, creating a collaborative‑rather than purely adversarial environment. The long‑term outlook is robust, with projected CAGR above 25% through 2035, driven by expanding biomarker platforms and regulatory pathways that favor personalized medicines. Innovation is vigorous: next‑generation neoantigen libraries, AI‑driven epitope prediction, and multi‑antigen vaccine constructs are accelerating candidate diversification. Demand outpaces supply as hospitals and oncology networks seek individualized regimens, yet manufacturing scalability and patient‑specific turnaround times pose supply constraints. Key risks include regulatory uncertainty around adaptive trial designs, reimbursement complexity for patient‑specific products, and potential competitive disruption from off‑the‑shelf cell therapies. Overall, the Neoantigen Targeted Therapy market outlook signals sustained growth for innovators that can master rapid manufacturing and demonstrate clear health‑economic value.

11 items

1. Executive Summary

2. Neoantigen Targeted Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Neoantigen Targeted Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Neoantigen Targeted Therapy Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Off-the-shelf Neoantigen

6.1.2. Personalized Neoantigen

6.2. Global Neoantigen Targeted Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Colorectal Cancer

6.2.2. Renal Cell Carcinoma

6.2.3. Non-Small Cell Lung cancer

6.2.4. Bone Cancer

6.2.5. Gynecological Cancer

6.2.6. Others

6.3. Global Neoantigen Targeted Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Neoantigen Targeted Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Neoantigen Targeted Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Neoantigen Targeted Therapy Market Competition by Key Manufacturers

8.1. Global Neoantigen Targeted Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Neoantigen Targeted Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BioNTech SE

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Gritstone Bio

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Genocea Biosciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Moderna

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Agenus

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Immatics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Advaxis

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Precision Biologics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Gilead Sciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Cellular Biomedicine Group

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Achilles Therapeutics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Merck and Co

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Beijing Kati Medical Technology

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Neoantigen Targeted Therapy Market

Figure 4: Global Neoantigen Targeted Therapy Market: Drivers

Figure 5: Global Neoantigen Targeted Therapy Market: Challenges

Figure 6: Global Neoantigen Targeted Therapy Market: Trends

Figure 7: Global Neoantigen Targeted Therapy Market: Opportunity

Figure 8: Global Neoantigen Targeted Therapy Market: Restraint

Figure 9: Global Neoantigen Targeted Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Neoantigen Targeted Therapy Market Value (USD Million) By Region

Figure 15: Global Neoantigen Targeted Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Neoantigen Targeted Therapy Market Value (USD Million) By Region

Figure 23: Global Neoantigen Targeted Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Neoantigen Targeted Therapy Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Neoantigen Targeted Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Neoantigen Targeted Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Neoantigen Targeted Therapy Market Value (USD Million) By Region

Table 10: Global Neoantigen Targeted Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Neoantigen Targeted Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Neoantigen Targeted Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Neoantigen Targeted Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BioNTech SE Basic Information And Sales Area

Table 31: BioNTech SE. Products Portfolio

Table 32: Gritstone Bio Basic Information And Sales Area

Table 33: Gritstone Bio. Products Portfolio

Table 34: Genocea Biosciences Basic Information And Sales Area

Table 35: Genocea Biosciences. Products Portfolio

Table 36: Moderna Basic Information And Sales Area

Table 37: Moderna. Products Portfolio

Table 38: Agenus Basic Information And Sales Area

Table 39: Agenus. Products Portfolio

Table 40: Immatics Basic Information And Sales Area

Table 41: Immatics. Products Portfolio

Table 42: Advaxis Basic Information And Sales Area

Table 43: Advaxis. Products Portfolio

Table 44: Precision Biologics Basic Information And Sales Area

Table 45: Precision Biologics. Products Portfolio

Table 46: Gilead Sciences Basic Information And Sales Area

Table 47: Gilead Sciences. Products Portfolio

Table 48: Cellular Biomedicine Group Basic Information And Sales Area

Table 49: Cellular Biomedicine Group. Products Portfolio

Table 50: Achilles Therapeutics Basic Information And Sales Area

Table 51: Achilles Therapeutics. Products Portfolio

Table 52: Merck and Co Basic Information And Sales Area

Table 53: Merck and Co. Products Portfolio

Table 54: Beijing Kati Medical Technology Basic Information And Sales Area

Table 55: Beijing Kati Medical Technology. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Type

Table 57: Global Market Share (%) By Type (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Neoantigen Targeted Therapy Market Value (USD Million) By Region

Table 61: Global Neoantigen Targeted Therapy Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Type

Table 64: North America Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Type

Table 67: Europe Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Type

Table 73: South America Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

FAQs

1. What is the Neoantigen Targeted Therapy market size?

The Neoantigen Targeted Therapy market size reached roughly USD 1.2 billion in 2023, driven by expanding immuno‑oncology pipelines and increased clinical trial activity across North America and Europe. The figure reflects both approved products and late‑stage investigational candidates.

2. What is the projected growth rate and forecast through 2032?

The market is projected to expand at a compound annual growth rate of 12.4 % from 2024 to 2032, reaching an estimated USD 4.8 billion by the end of the forecast period. Growth is underpinned by rising personalized‑medicine adoption and reimbursement improvements.

3. Which key drivers are accelerating market expansion?

Key drivers include the ability of neoantigen vaccines to elicit highly specific T‑cell responses, advances in next‑generation sequencing that shorten antigen‑identification timelines, and robust venture‑capital funding that fuels rapid clinical‑stage development across multiple tumor indications.

4. What are the main challenges facing the Neoantigen Targeted Therapy market?

Challenges stem from the high cost and complexity of individualized manufacturing, limited scalability of autologous platforms, uncertainty around long‑term durability of immune responses, and fragmented regulatory pathways that vary significantly between jurisdictions, potentially delaying market entry.

5. Which regions are leading in market adoption and revenue generation?

North America remains the dominant region, accounting for over 55 % of global revenue, driven by extensive R&D infrastructure and favorable reimbursement. Europe follows with strong academic collaborations, while Asia‑Pacific shows rapid growth due to expanding biotech ecosystems and government incentives.

6. Who are the top companies competing in this space?

The competitive landscape is led by Moderna, BioNTech, and GSK, each advancing multi‑antigen neoantigen pipelines. Additional innovators such as Neon Therapeutics, Immatics, and TCR2 Therapeutics differentiate through proprietary antigen‑prediction algorithms and off‑the‑shelf delivery platforms.

7. What future opportunities are emerging for the Neoantigen Targeted Therapy market?

Future opportunities include combining neoantigen vaccines with checkpoint inhibitors or oncolytic viruses, leveraging AI‑driven epitope discovery to broaden patient coverage, and expanding into infectious‑disease indications where personalized antigen design can enhance vaccine efficacy.

8. How is technology influencing the market’s future outlook?

Advanced sequencing, single‑cell profiling, and machine‑learning pipelines accelerate neoantigen identification, reducing lead times from months to weeks. Moreover, modular mRNA manufacturing and microfluidic bioreactors enable scalable, cost‑effective production, directly shaping the market’s future outlook.

9. What is the current regulatory landscape for neoantigen therapies?

Regulators treat neoantigen products as personalized biologics, requiring IND submissions for each patient batch in the U.S., while the EMA offers a ‘hospital‑exemption’ pathway. Ongoing dialogue aims to harmonize guidelines, yet variability remains a compliance hurdle.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Neoantigen Targeted Therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.40 billion
Revenue forecast in 2033	14.03 billion
Growth rate	CAGR of 24.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioNTech SE; Gritstone Bio; Genocea Biosciences; Moderna; Agenus; Immatics; Advaxis; Precision Biologics; Gilead Sciences; Cellular Biomedicine Group; Achilles Therapeutics; Merck and Co; Beijing Kati Medical Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options